Biotech pharma

XGenomes

Website

At XGenomes, we are building a technology comprising novel biochemistry, hardware and algorithms for sequencing DNA. Our product will be streamlined: there is zero library preparation; we sequence directly on unadulterated single molecules of DNA; DNA extraction will be integrated with sequencing; there is no bioinformatics bottleneck. The sequen

Founded 2017Origin source ↗Checked 2026-09-15

Overview

At XGenomes, we are building a technology comprising novel biochemistry, hardware and algorithms for sequencing DNA. Our product will be streamlined: there is zero library preparation; we sequence directly on unadulterated single molecules of DNA; DNA extraction will be integrated with sequencing; there is no bioinformatics bottleneck. The sequence we produce will be of unprecedented accuracy due to several layers of in-built redundancy including the sequencing both strands of the double-helix concurrently. The sequence we produce will be complete, encompassing: structural as well as single nucleotide variants; long-range haplotype phase; the repetitive "dark matter" of the genome. The cost of goods (consumables) of sequencing will be <$10, which will allow us to price our product at a level that will help grow the market while still achieving >90% margin. We will start by offering access as a service to high value customers, which be followed by a razor and blade model of selling instruments and consumables.

Company description As recorded 2026-11-08
LinkedIn
Biotech pharmaHardware deviceBusinessesEnterpriseHardware sales

Founders & team

Previously XGenomes Corp.

Company history As recorded 2026-11-08
6team members reported
Source-reported As recorded 2026-09-15

Founded 2017 · Source

News & product activity

Sources & observations

Y Combinator

Profile depthverified profile
Website observationwebsite reachable
Last website check2026-11-11
Location · source statedBoston, MA, USA; Cambridge, MA, USA
Pricing evidenceNo pricing page confirmed
Maturity: Not assessed · 3 of 6 areas documented

Source-based assessment · automated evidence rules

The retained text does not establish product availability or customer use.

Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.

Stage definitions
independent websitesource corroborationreachable websitedescriptive evidenceclassified market and modelsourced peoplesourced founding year
startup.observe Directory coverage · Sources & method